FEDERAL COURT OF AUSTRALIA
Merial, Inc. v Intervet International B.V. (No 3) [2017] FCA 21
File number: VID 399 of 2015 Judge: MOSHINSKY J Date of judgment: 25 January 2017 Catchwords: PATENTS – appeal under s 60(4) of the Patents Act 1990 (Cth) – entitlement – where opponent contended that applicant for patent did not derive title to alleged invention from inventor – where invention described in patent application was a soft chew formulation for administering an anti-parasite pharmaceutical to certain animals – whether opponent clearly established lack of entitlement
PATENTS – appeal under s 60(4) of the Patents Act 1990 (Cth) – inventive step – obviousness – where opponent contended that alleged invention lacked an inventive step – person skilled in the relevant art – the common general knowledge – information mentioned in s 7(3) of the Patents Act – whether applicant clearly established lack of inventive step
Legislation: Evidence Act 1995 (Cth), s 140
Intellectual Property Laws Amendment (Raising the Bar) Act 2012 (Cth)
Patents Act 1952 (Cth), s 100(1)(e)
Patents Act 1990 (Cth), ss 7, 15, 18, 40, 59, 60(4)
Patents Amendment Act 2001 (Cth)
Cases cited: Abraxis Bioscience, Inc v Navinta LLC, 625 F 3d 1359 (Fed Cir 2010)
Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411
Allegheny Steel & Brass Corp v Elting, 141 F 2d 148 (7th Cir 1944)
AstraZeneca AB v Apotex Pty Ltd (2015) 323 ALR 605
Baltimore & Ohio R Co v United States, 261 US 592 (1923)
Banks v Unisys Corp, 228 F 3d 1357 (Fed Cir 2000)
Bd of Trustees of the Leland Stanford Junior University v Roche Molecular Systems, 563 US 776 (2011)
Bldg Innovation Indus, LLC v Onken, 473 F Supp 2d 978 (D Ariz 2007)
Commissioner of Patents v Microcell Ltd (1959) 102 CLR 232
Commissioner of Patents v Sherman (2008) 172 FCR 394
EI Du Pont de Nemours and Company v ICI Chemicals & Polymers Ltd (2003) 128 FCR 392
Enzo Apa & Son, Inc v Gaepag AG, 134 F 3d 1090 (Fed Cir 1998)
F Hoffman-La Roche AG v New England Biolabs Inc (2000) 99 FCR 56
Gilson v Commissioner, Docket No 3801-78, 1984 Tax Ct Memo LEXIS 228 (US TC Aug 21, 1984)
Hercules, Inc v US, 516 US 417 (1996)
Intervet International B.V. v Merial Inc [2016] FCA 1030
Kaiser v Millard Lumber, Inc, 25 Neb 943; 587 NW 2d 875 (1999)
Lockwood Security Products Pty Ltd v Doric Products Pty Ltd (No 2) (2007) 235 CLR 173
Mellon Bank, N.A. v Aetna Business Credit, 619 F 2d 1001 (3rd Cir 1980)
Minnesota Mining and Manufacturing Co v Beiersdorf (Australia) Ltd (1980) 144 CLR 253
Olin Mathieson Chemical Corporation v Biorex Laboratories Ltd [1970] RPC 157
SiRF Tech, Inc v Int’l Trade Comm’n, 601 F…
Keep reading for free
Create a free CaseChat account to read Merial, Inc. v Intervet International B.V. (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2017] FCA 21
- Decision Date
CaseChat Overview and Summary
The primary legal issues before the court were whether the opponent had clearly established a lack of entitlement to the patent and whether the invention lacked an inventive step. The court considered whether the applicant had derived the title to the alleged invention from the inventor and whether the invention was obvious to a person skilled in the relevant art, taking into account the common general knowledge and the information mentioned in section 7(3) of the Patents Act 1990 (Cth).
In reaching its decision, the court found that the opponent had clearly established the lack of entitlement to the patent. Consequently, the court did not need to determine the issue of inventive step. Nevertheless, for the sake of completeness, the court examined the inventive step issue and concluded that it was partially made out. The court ordered the parties to file an agreed minute of proposed orders to give effect to the reasons or, if they could not agree, to file and serve their respective minutes of proposed orders, together with a short outline of submissions in support.
The court's final orders required the parties to file an agreed minute of proposed orders by a specified date or, if they could not agree, to file and serve their respective minutes of proposed orders, together with a short outline of submissions in support. The orders also referred to Rule 39.32 of the Federal Court Rules 2011 for the entry of orders.
Orders
Orders of the court
1. Subject to paragraph 2, by 4.00 pm on 3 February 2017, the parties file an agreed minute of proposed orders to give effect to these reasons.
2. If the parties cannot agree, then by 4.00 pm on 10 February 2017, each party file and serve a minute of proposed orders to give effect to these reasons, together with a short outline of submissions in support of those proposed orders.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
This matter is an appeal under section 60(4) of the Patents Act 1990 (Cth) from a decision of the first instance hearing where the patent application was contested on the grounds of lack of entitlement and lack of inventive step. The appeal was heard by the court, which reviewed the submissions and evidence from both parties, including the detailed documentation provided by Pharma Chemie. The court's decision focused on whether Intervet was entitled to the patent and whether the invention met the criteria for patentability, particularly in terms of inventive step and entitlement.
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
On or about 20 October 2003, Ms Marsh on behalf of Pharma Chemie sent another letter to Mr Ramey. The letter was headed: “Re: Patent Application Entitled ‘Novel Compositions and Processes for Delivering an Additive’; Copies of Petition Under 37 CFR §1.47 Filed with Patent and Trademark Office” and was in the following terms:Dear Mr. Ramey:Our client forwarded us the above-referenced petition for an inventor who refuses to sign. As explained in our letter of September 16, 2003, Mr. Pieloch will not sign the Declaration and Power of Attorney for this application since Pharma Chemie, not Intervet, invented its subject matter.We note in your petition and sworn statement that was apparently submitted to the PCT that, as of September 22, 2003, neither Mr. Pieloch nor his attorney had attempted to communicate with you. However, this statement is obviously not true in view of our September 16th letter. We trust you will be promptly informing the U.S. receiving office of this communication.Since Intervet did not invent the subject matter of the above-referenced patent application, any U.S. patent application filed by Intervet on this technology (if one has not been filed already) will be unpatentable under 35 U.S.C. §102(f). Attached please find evidence proving Mark Pieloch as the inventor of the soft chew formulation described in your application. The active ingredients of the formulations have been blacked out, but not their concentrations, so you can readily ascertain the concentrations of inactive ingredients, including the “starch component”, “sugar component”, “oil component”, and a “first additive” whereby the moisture content is less than about 15%. If a U.S. application is (or has already been) filed, under 37 C.F.R. §1.56, you will be obligated to disclose this evidence to the Patent Office as it is all material to the patentability of the Intervet application. Please note that this information must be treated as confidential according to the terms of the confidential disclosure agreement of the parties dated October 16, 2001, except for purposes of meeting your duty of disclosure under Rule 56.Very truly yours,[signed]WENDY K. MARSH(Emphasis added.) Ms Marsh’s letter attached a four-page letter from Mr Pieloch to her dated 6 October 2003, together with an eight-page summary of the attachments to that letter and 19 attachments. The subject of Mr Pieloch’s letter was: “Collaborated Documentation of Pharma Chemie’s Soft Chew Product Development Activities from 1992-2002”. The first paragraph of the letter stated in part:This letter with its numerous attachments is just a small sampling of documentation that is being provided to you to document the fact that the “Soft Chew” technology was developed not by Intervet in 2002, but was well developed by Pharma Chemie in numerous forms starting in 1992 and continuing to this day.Mr Pieloch’s letter contained a chronological summary of certain matters and then stated (at p 3):Thus, I have attempted to present a chronological history of collaborated “Soft Chew” product development activities, which clearly shows that Pharma Chemie possessed the “Soft Chew” technology prior to any development work being undertaken by Pharma Chemie for Intervet in the spring of 2002.Mr Pieloch’s letter also referred (on p 3) to “Intervet’s US Patent Application, Serial Number: PCT/US03/25358”, which is the number for the PCT Application, and made some observations about the patent application. Mr Pieloch was cross-examined extensively on the attachments to his letter dated 6 October 2003. I refer to this evidence later in these reasons.